相关实验视频

Updated: Sep 8, 2025

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

在α-synucleinopathies连续性的皮层抑制和促进性改变

Andrea Rizzardi¹, Alberto Benussi², Cinzia Zatti¹

¹Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy; Laboratory of Digital Neurology and Biosensors, University of Brescia, Italy.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

|July 25, 2025

概括

跨磁刺激 (TMS) 揭示了像帕金森病这样的α-synucleinopathies中的早期GABAergic,胆固醇和谷氨酸功能障碍,有助于诊断和监测.

科学领域:

神经科学是一个神经科学.
神经学神经学
生物标志物发现发现

背景情况:

包括帕金森病 (PD),勒维体痴呆症 (DLB) 和异常REM睡眠行为障碍 (iRBD) 在内的α-synucleinopathies,以α-synuclein蛋白聚合为特征.
这些神经退行性疾病的早期诊断和监测仍然具有挑战性,需要开发可靠的生物标志物.

研究的目的:

通过使用跨磁刺激 (TMS) 来研究alpha-synucleinopathies中的皮层内抑制和促进电路的改变.
评估TMS衍生措施作为早期诊断,疾病分层和疾病进展监测的生物标志物的潜力.

主要方法:

招募从未使用过药物的PD患者 (n=45),DLB患者 (n=20),iRBD患者 (n=15) 和健康对照 (HC,n=20).
标准化临床评估和TMS配对脉冲协议,以测量短间隔内皮层抑制 (SICI),短延迟附带抑制 (SAI) 和内皮层促进 (ICF).

主要成果:

与HC相比,PD,iRBD和DLB中的SICI减少,表明早期的GABAergic功能障碍.
在iRBD和DLB中受损的SAI,但在PD中保留,表明特定的胆功能障碍.
改变了DLB中的ICF和iRBD中的变量变化,表明异质的谷氨酸干涉.

结论:

在前阶段的α-synucleinopathies中存在皮层抑制和促进异常.
在iRBD和DLB中,胆功能障碍可能作为认知风险的早期生物标志物.
作为早期检测,患者分层和监测alpha-synucleinopathies疾病进展的生物标记工具,TMS显示出希望.

关键词:

阿尔法同核蛋白病变 (alpha-synucleinopathies) 是一种同核蛋白病变.抑制和促进的电路.帕金森病是帕金森氏症的一种疾病.这是一个prodromal阶段.通过骨磁刺激进行磁性刺激.

更多相关视频

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

相关概念视频

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Excitatory and Inhibitory Effects of Neurotransmitters

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...